Accesso libero

Shear wave elastography reveals a high prevalence of liver fibrosis in overweight or obese Hispanic youth

Sanjeet Sandhu
Sanjeet Sandhu
, 
Carisse Orsi
Carisse Orsi
, 
Gary L. Francis
Gary L. Francis
, 
Zhu Wang
Zhu Wang
, 
Roman Fernandez
Roman Fernandez
 e 
Naim Alkhouri
Naim Alkhouri
   | 28 set 2020
Journal of Ultrasonography's Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Article Category: research-article
Pubblicato online: 28 set 2020
Pagine: 162 - 168
Ricevuto: 09 mar 2020
Accettato: 07 lug 2020
DOI: https://doi.org/10.15557/jou.2020.0027
Parole chiave
© 2021 Polish Ultrasound Society. Published by Medical Communications Sp. z o.o.
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Fig. 1.

The association between serum AST (U/L) and SWE score as measured using SWE in kPa. The overall association was not significant (p = 0.08) and there were several patients with elevation in SWE score, but normal AST, while others had marked elevations in AST, but no elevation in SWE score. AST – aspartate aminotransferase; SWE Score – liver stiffness measured in kilopascals (kPa)
The association between serum AST (U/L) and SWE score as measured using SWE in kPa. The overall association was not significant (p = 0.08) and there were several patients with elevation in SWE score, but normal AST, while others had marked elevations in AST, but no elevation in SWE score. AST – aspartate aminotransferase; SWE Score – liver stiffness measured in kilopascals (kPa)

Fig. 2.

The association between serum ALT (U/L) and SWE score as measured using SWE in kPa. The overall association was not significant (p = 0.07) and there were several patients with elevation in SWE score, but normal ALT, while others had marked elevations in ALT, but no elevation in SWE score. ALT – alanine aminotransferase; SWE Score – liver stiffness measured in kilopascals (kPa)
The association between serum ALT (U/L) and SWE score as measured using SWE in kPa. The overall association was not significant (p = 0.07) and there were several patients with elevation in SWE score, but normal ALT, while others had marked elevations in ALT, but no elevation in SWE score. ALT – alanine aminotransferase; SWE Score – liver stiffness measured in kilopascals (kPa)

Fig. 3.

The association between A1c (%) and SWE score as measured using SWE in kPa. The overall association was not significant (p = 0.44) and there were several patients with elevation in SWE score, but normal A 1c , while others had marked elevations in A 1c , but no elevation in SWE score. A 1c – glycohemoglobin; SWE Score – liver stiffness measured in kilopascals (kPa)
The association between A1c (%) and SWE score as measured using SWE in kPa. The overall association was not significant (p = 0.44) and there were several patients with elevation in SWE score, but normal A 1c , while others had marked elevations in A 1c , but no elevation in SWE score. A 1c – glycohemoglobin; SWE Score – liver stiffness measured in kilopascals (kPa)

Fig. 4.

The association between BMI SD and SWE score as measured using SWE in kPa. The overall association was not significant (p = 0.43) and there were several patients with elevation in SWE score, but only modest elevation in BMI SD (1.5–2.0), while others had marked elevations in BMI-SD (2.0–3.5), but no elevation in SWE score. BMI SD – body mass index standard deviation score for age; SWE Score – liver stiffness measured in kilopascals (kPa)
The association between BMI SD and SWE score as measured using SWE in kPa. The overall association was not significant (p = 0.43) and there were several patients with elevation in SWE score, but only modest elevation in BMI SD (1.5–2.0), while others had marked elevations in BMI-SD (2.0–3.5), but no elevation in SWE score. BMI SD – body mass index standard deviation score for age; SWE Score – liver stiffness measured in kilopascals (kPa)

Fig. 5.

The association between APRI and SWE score as measured using SWE in kPa. The overall association was not significant (p = 0.16) and there were several patients with elevation in SWE score, but normal APRI, while others had marked elevations in APRI, but no elevation in SWE score. SWE Score – liver stiffness measured in kilopascals (kPa); APRI – aspartate aminotransferase (AST)/platelet ratio index
The association between APRI and SWE score as measured using SWE in kPa. The overall association was not significant (p = 0.16) and there were several patients with elevation in SWE score, but normal APRI, while others had marked elevations in APRI, but no elevation in SWE score. SWE Score – liver stiffness measured in kilopascals (kPa); APRI – aspartate aminotransferase (AST)/platelet ratio index

Demographic and laboratory features of patients stratified by A1c

Entire cohort N = 67 Group CNormal A1c (<5.7%) N = 35Mean ± SD (range) Group DAbnormal A1c (≥5.7%) N = 32Mean ± SD (range) P = for Group Cvs. Group D
Age (yr) 13.59(8–18) 12.97(8–18) 14.25(8–18) 0.087
Gender Male = 35Female = 32 Males = 18Female = 14 Males = 17Female = 18 0.529
BMI SDS 2.49 ± 0.39(1.45–3.37) 2.39 ± 0.38(1.45–3.11) 2.53 ± 0.40(1.94–3.37) 0.169
Serum ALT (U/L) 78.48 ± 44.75(19–189) 82.41 ± 45.63(19–185) 74.16 ± 44.10(23–189) 0.462
Serum AST (U/L) 40.1 ± 22.1(11–110) 40.09 ± 18.54(19–110) 40.13 ± 25.74(11–106) 0.994
A1c (%) 5.77 ± 0.64(4.5–7.9) 5.36 ± 0.23(4.5–5.6) 6.19 ± 0.66(5.7–7.9) <0.001
SWE Score (kPa) 5.61 ± 1.43(1.47–10.45) 5.82 ± 1.48(2.69–10.45) 5.39 ± 1.36(1.47–9.85) 0.233
HOMA-IR 10.62 ± 10.19(2.84–49.24) 10.49 ± 12.04(2.84–49.24) 10.84 ± 6.47(4.61–25.25) 0.940
Vitamin D, 25OH (ng/mL) 14.23 ± 5.44(6–28) 11.80 ± 4.18(6–20) 15.75 ± 5.65(7–28) 0.025
Platelets (× 109 per liter) 310 ± 75.50(187–490) 299.89 ± 66.38(217–455) 326.46 ± 76.01(187–490) 0.303
APRI 0.40 ± 0.25(0.12–1.19) 0.42 ± 0.24(0.16–1.19) 0.36 ± (0.28)(0.12–1.01) 0.494
Metformin users 8 1 patient 7 patients 0.016

Demographic and laboratory features of patients with (SWE Score >5.10 kPa) and without (SWE Score <5.1 kPa) suspected hepatic fibrosis

Entire cohort N = 67 Group ANo suspected fibrosis(SWE score <5.10 kPa) N = 25Mean ± SD (range) Group BSuspected fibrosis(SWE score ≥5.10 kPa) N = 42Mean ± SD (range) P = for Group Avs. Group B
Age (yr) 13.59(8–18) 13.12 ± 2.80(8–18) 13.88 ± 3.10(8–18) 0.328
Gender Male = 35Female = 32 Male = 15Female = 10 Male = 20Female = 22 0.326
BMI SDS 2.49 ± 0.39(1.45–3.37) 2.42 ± 0.40(1.45–3.37) 2.48 ± 0.38(1.66–3.22) 0.603
Serum ALT (U/L) 78.48 ± 44.75(19–189) 60.04 U/L ± 41.01(19–181) 89.27 U/L ± 43.75(23–189) 0.010
Serum AST (U/L) 40.1 ± 22.1(11–110) 31.12 U/L ± 14.92(14–75) 45.37 U/L ± 23.99(11–110) 0.011
A1c (%) 5.77 ± 0.64(4.5–7.9) 5.71 ± 074(5.0–7.0) 5.80 ± 0.74(4.5–7.9) 0.557
SWE Score (kPa) 5.61 ±1.43(1.47–10.45) 4.47 ±0.83(1.47–5.06) 6.28 ± 1.28(5.2–10.45) <0.001
HOMA-IR 10.62 ± 10.19(2.84–49.24) 14.25 ± 14.85(3.38–49.24) 8.55 ± 4.36(2.84–17.40) 0.215
Vitamin D, 25OH (ng/mL) 14.23 ± 5.44(6–28) 14.60 ± 5.42(7–28) 14.00 ± 5.55(6–25) 0.742
Platelets (× 109 per liter) 310 ± 75.50(187–490) 325.67 ± 45.40(276–452) 301.70 ± 81.79(187–490) 0.360
APRI 0.40 ± 0.25(0.12–1.19) 0.25± 0.13(0.12–0.38) 0.49 ± 0.27(0.16–1.19) 0.011
Metformin users 8 2 patients 6 patients 0.442

Demographic and laboratory features of patients who underwent liver biopsy

Subjects with liver biopsy N = 5
Age (yr) 14.00 (8–17)
Fibrosis stage Stage 1= 4 patientsStage 2 = 1 patient
Gender Male = 3Female = 2
BMI SDS 2.44 ± 0.55 (1.66–3.11)
Serum ALT (U/L) 133.20 ± 49.70 (86–189)
Serum AST (U/l) 76.40 ± 33.20 (34–110)
A1c (%) 6.15 ± 0.93 (5.4–7.4)
SWE score (kPa) 7.45 ± 1.43 (6.05–10.45)
Vitamin D 25OH (ng/mL) 9.75 ± 2.22 (9–13)
Platelets (× 109 per liter) 277.10 ± 76.07 (187–431)
AST/PLT ratio 0.64 ± 0.41 (0.33–1.52)
Metformin users N = 2
eISSN:
2451-070X
Lingua:
Inglese
Frequenza di pubblicazione:
4 volte all'anno
Argomenti della rivista:
Medicine, Basic Medical Science, other
Feed RSS della rivista